Membrane-disrupting antimicrobial peptides (AMPs) have long been considered possible alternate therapeutics for the fight against drug-resistant bacteria. Yet, development of AMPs into drugs is almost absent.
We have quantified some of the major impediments to systemic clinical utility of AMPs:
We are doing two things to solve the problem. 1) We are characterizing these impediments for a better understanding, and 2) We are using the knowledge to enable synthetic molecular evolution of novel AMPs that simultaneously avoid all of the impediments to clinically useful activity.
He J, Starr CG, Wimley WC. A lack of synergy between membrane-permeabilizing cationic antimicrobial peptides and conventional antibiotics. Biochim Biophys Acta. 2015 Jan;1848(1 Pt A):8-15. doi PubMed PMC
He J, Krauson AJ, Wimley WC. Toward the de novo design of antimicrobial peptides: Lack of correlation between peptide permeabilization of lipid vesicles and antimicrobial, cytolytic, or cytotoxic activity in living cells. Biopolymers. 2014 Jan;102(1):1-6. doi. PubMed PMC
Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011 Jan;239(1-2):27-34. doi. PubMed PMC (Collaboration with the Hristova Lab at Johns Hopkins)
Rathinakumar R, Walkenhorst WF, Wimley WC. (2009) Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J Am Chem Soc. 2009 Jun 10;131(22):7609-17 doi PubMed PMC
Rathinakumar R, Wimley WC. (2008) Biomolecular engineering by combinatorial design and high-throughput screening: small, soluble peptides that permeabilize membranes. J Am Chem Soc. 2008 Jul 30;130(30):9849-58. doi PubMed PMC